Venous thromboembolism in patients with inflammatory bowel diseases: A case-control study of risk factors

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 631-636

  Scoville, Elizabeth A ^a   Konijeti, Gauree G ^a   Nguyen, Deanna D ^a,b   Sauk, Jenny ^a,b   Yajnik, Vijay ^a,b   Ananthakrishnan, Ashwin N ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Celiac disease; Crohn's disease; Prophylaxis; Thrombosis; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; ANTICOAGULANT AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTRA ABDOMINAL THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; MIDDLE AGED; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM; AGED; COLITIS, ULCERATIVE; DISEASE COURSE; HORMONE SUBSTITUTION; INDWELLING CATHETER; NEOPLASMS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA;

ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; CATHETERS, INDWELLING; COLITIS, ULCERATIVE; CONTRACEPTIVES, ORAL; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HORMONE REPLACEMENT THERAPY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84898728642     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000007     Document Type: Article

References (31)

1. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430-434.
2. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937-943.
3. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch Surg. 2012;147:120-124.
4. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011; 106:713-718.
5. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272-2280.
6. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779-787, 787 e1.
7. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167:935-943.
8. Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:953-962.
9. Saleh T, Matta F, Yaekoub AY, et al. Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost. 2010;17:254-258.
10. Jess T, Gamborg M, Munkholm P, et al. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102:609-617.
11. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657-663.
12. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195.
13. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
14. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523; quiz 524.
15. Baser O, Liu X, Phatak H, et al. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther. 2013;20:132-142.
16. Nalichowski R, Keogh D, Chueh HC, et al. Calculating the benefits of a research patient data Repository. AMIA Annu Symp Proc. 2006:1044.
17. Oxford EC, Nguyen DD, Sauk J, et al. Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol. 2013;108:1123-1129.
18. de Silva PS, Nguyen DD, Sauk J, et al. Long-term outcome of a third anti- TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:459-466.
19. Koutroumpakis EI, Tsiolakidou G, Koutroubakis IE. Risk of venous thromboembolism in patients with inflammatory bowel disease. Semin Thromb Hemost. 2013;39:461-468.
20. Nguyen GC, Yeo EL. Prophylaxis of venous thromboembolism in IBD. Lancet. 2010;375:616-617.
21. Papay P, Miehsler W, Tilg H, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis. 2013;7:723-729.
22. Mean M, Righini M, Jaeger K, et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis. 2013;36:475-483.
23. Maestre A, Sanchez R, Rosa V, et al. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry. Eur J Intern Med. 2010;21:377-382.
24. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167:1471-1475.
25. Nguyen GC, Sharma S. Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm Bowel Dis. 2013;19:2182-2189.
26. Sharma A, Chatterjee S, Lichstein E, et al. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012;10:2053-2060.
27. Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin Ther. 2009;31:1129-1141.
28. Ojo P, Asiyanbola B, Valin E, et al. Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? Obes Surg. 2008;18: 791-796.
29. Scarpa M, Pilon F, Pengo V, et al. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg. 2010;34:1629-1636.
30. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146:278-288.
31. Sam JJ, Bernstein CN, Razik R, et al. Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci. 2013;58:46-52.